Variotide LAR ® (Octreotide Acetate) 20, 30 mg

Variotide is a Somatostatin Analog used to treat certain growth disorders and diarrhea related to some cancers.

Powder and Solvent for Solution - For injection, One Month Depot

Acromegaly: Initial: 20 mg SC intragluteally every 4 weeks for 3 months. Adjust dose as necessary based on clinical response. Dosage adjustments based on GH, IGF-1 levels, and symptom control:
GH ≤1 ng/mL, IGF-1 normal, and symptoms controlled: Reduce to 10 mg every 4 weeks.
GH >1 to ≤2.5 ng/mL, IGF-1 normal, and symptoms controlled: Maintain at 20 mg every 4 weeks.
GH >2.5 ng/mL, IGF-1 elevated, and/or symptoms uncontrolled: Increase to 30 mg every 4 weeks. Further dose increase to 40 mg if needed. Doses >40 mg not recommended, but up to 60 mg every 4 weeks used in some cases.
Carcinoid Syndrome and VIPomas:
Initial: 20 mg SC intragluteally every 4 weeks or 20 to 30 mg SC intragluteally every 4 weeks.
Dose adjustments based on response:
Decrease to 10 mg every 4 weeks after 2 months if initially responsive to 20 mg dose.
Increase to 30 mg every 4 weeks if symptoms inadequately controlled after 2 months.

Cholelithiasis and related complications

Glucose dysregulation

Necrotizing enterocolitis

Diarrhea (36.4%)

Abdominal pain or discomfort (29.1%)

Hyperglycemia (27%)

Flatulence (25.7%)

Sinus bradycardia (<50 bpm) (25%)

Constipation (18.8%)

Biochemical hypothyroidism (12%)

Nausea (10.3%)

Macimorelin: Avoid combination.
Fexinidazole: Avoid combination.
QT-prolonging Agents (e.g., Disopyramide, Ibutilide, Indapamide, Pentamidine, Pimozide, Procainamide, Quinidine, Sotalol): Contraindicated due to increased QTc interval.

Store at 2 - 8 °C (in refrigerator) and protect from light and freezing.
Keep Variotide LAR® out of the sight and reach of children.